Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASE-3 empagliflozin adjunct to insulin in adults with type 1 diabetes
NL-OMON44650Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of empagliflozin in diabetes mellitus type 1 (T1D) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change from baseline in glycated hemoglobin. Started Jan 2016; status: active, not recruiting.
02
Drugs
empagliflozin
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on NL-OMON44650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44650.